Pay in 4 interest-free payments of $6.99 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status
The clinical trial data gives us a remarkably detailed picture of the weight loss trajectory, and it does not follow a straight line
On the following day, a luciferase detection reagent was added, before luminescence was measured
Tian B, Deng Y, Cai Y, Han M, Xu G
Together, they promote sustained energy, healthy metabolism, and overall vitality
US$ 21.95
US$ 25.42
US$ 21.72
US$ 25.15
US$ 24.10
US$ 26.84
